Free Trial
NASDAQ:AWH

Aspira Women's Health Q4 2024 Earnings Report

Aspira Women's Health EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.21
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Aspira Women's Health Revenue Results

Actual Revenue
$2.35 million
Expected Revenue
$3.00 million
Beat/Miss
Missed by -$650.00 thousand
YoY Revenue Growth
N/A

Aspira Women's Health Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 27, 2025
Conference Call Time
10:30AM ET

Aspira Women's Health Earnings Headlines

An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.tc pixel
See More Aspira Women's Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aspira Women's Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aspira Women's Health and other key companies, straight to your email.

About Aspira Women's Health

Aspira Women's Health (NASDAQ:AWH), Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.

View Aspira Women's Health Profile

More Earnings Resources from MarketBeat